Necrotizing Enterocolitis
Conditions
Keywords
galacto-oligosaccharides, prebiotics, NEC
Brief summary
Necrotizing enterocolitis (NEC) is the most common gastrointestinal catastrophe affecting 10-15% of premature neonates of \<1500 gm. NEC is a disease of the immature intestine, characterized by impaired mucosal barrier function leading to increased gut permeability. We have previously demonstrated a protective effect of probiotic administration against the development of NEC. Others have shown that prebiotics can stimulate natural production of bifidobacteria and lactobacillus in the preterm gut. We have therefore hypothesized that prophylactic administration of prebiotics would also provide protection against necrotizing enterocolitis in the premature neonate, without the potential for sepsis which has been reported on rare occasions with probiotics administration.
Detailed description
Specifically, we hope to demonstrate that fewer of the babies who are treated with galacto-oligosaccharides (GOS) will develop NEC as compared with controls. Preterm neonates, \<1750 gm birth weight will potentially be candidates for study. They will be randomly assigned to receive one of two milk additives from the time enteral feeds are begun until 35 weeks post-conceptual age: prebiotics (GOS) or placebo (water). All infants will be followed prospectively for signs of feeding intolerance and/or development of NEC. These will be compared between the two groups.
Interventions
Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
Similar quantity of sterile water to be added to milk
Sponsors
Study design
Eligibility
Inclusion criteria
* Preterm neonates * \< 1750 gm birth weight
Exclusion criteria
* Infants who are deemed unlikely to survive * Infants with significant congenital malformations * Infants with other gastrointestinal problems
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Necrotizing Enterocolitis | yearly |
Secondary
| Measure | Time frame |
|---|---|
| fecal calprotectin, urine IFABP | end of study |
| NEC related morbidity, ie. perforation, surgery [including peritoneal drain placement] | yearly |
| Stool bifidobacteria | End of study |
Countries
Israel